The overarching goal of the UCSF-GIVI CFAR Pharmacology Core Laboratory is to provide state-of-the-art pharmacological tools that can be used to optimize therapy in HIV-infected subjects. This core is staffed by experienced pharmacologists who provide expertise and advice for analytical development, trial design, and preclinical or clinical pharmacokinetic (PK) and pharmacodynamic (PD) data analysis. The Core maintains a broad array of innovative pharmacological assays including plasma, intracellular, unbound and tissue assays to support international and domestic research related to malaria, tuberculosis and HIV co-infections, health disparities among women and children, HIV latency and HIV infection in aging populations. The efforts around HIV pathogenesis and viral eradication specifically extend activities ongoing in the CFAR Virology and Immunology Cores. The Pharmacology Core provides three complementary services that together provide added value over that available in more conventional pharmacology laboratories - 1) specialized pharmacological assays customized to CFAR investigators'needs;2) research through support of key CFAR initiatives;and 3) education and training in pharmacological analytical methods, study design and analysis for the next generation of translational scientists. A new emphasis of the Core is the support of international research including established CFAR-related programs in Kampala and Tororo, Uganda and a nascent program in Harare, Zimbabwe. During the past funding cycle, core users have published or submitted 26 manuscripts including results for translational studies on the penetration of HIV drugs into sanctuary sites, HIV pathogenesis, metabolic effects of HIV drugs, malaria and tuberculosis pharmacology and the PK and PD of critical therapies in children and women. During the past four years, the Core has assisted in over 40 investigations and has analyzed over 10,000 samples using more than 30 distinct assays. Investigators in the Pharmacology Core have mentored 17 trainees during the past funding cycle including scientists from international sites. In terms of international activities, the Pharmacology Core is actively engaged in building capacity for pharmacology research at Makerere University in Kampala, Uganda.

Public Health Relevance

The CFAR Pharmacology Core is dedicated to promoting pharmacology research within the HIV epidemic to improve treatments for primary infection, co-infections and for vulnerable populations and to extend knowledge gained through pathogenesis and eradication studies. The Core provides broad-reaching expertise for novel pharmacological analytical methods and PK/PD study design and analysis. The Core is dedicated to supporting research relevant to both domestic and international settings, working closely with international sites to build capacity for pharmacology research.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-RRS-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
Dubé, Karine; Gianella, Sara; Concha-Garcia, Susan et al. (2018) Ethical considerations for HIV cure-related research at the end of life. BMC Med Ethics 19:83
Libby, Ashley Rg; Joy, David A; So, Po-Lin et al. (2018) Spatiotemporal mosaic self-patterning of pluripotent stem cells using CRISPR interference. Elife 7:
Haas, Andreas D; Zaniewski, Elizabeth; Anderegg, Nanina et al. (2018) Retention and mortality on antiretroviral therapy in sub-Saharan Africa: collaborative analyses of HIV treatment programmes. J Int AIDS Soc 21:
Jin, Harry; Ogunbajo, Adedotun; Mimiaga, Matthew J et al. (2018) Over the influence: The HIV care continuum among methamphetamine-using men who have sex with men. Drug Alcohol Depend 192:125-128
Manuzak, Jennifer A; Gott, Toni M; Kirkwood, Jay S et al. (2018) Heavy Cannabis Use Associated With Reduction in Activated and Inflammatory Immune Cell Frequencies in Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Individuals. Clin Infect Dis 66:1872-1882
Jiang, Guochun; Nguyen, Don; Archin, Nancie M et al. (2018) HIV latency is reversed by ACSS2-driven histone crotonylation. J Clin Invest 128:1190-1198
Hansen, Maike M K; Desai, Ravi V; Simpson, Michael L et al. (2018) Cytoplasmic Amplification of Transcriptional Noise Generates Substantial Cell-to-Cell Variability. Cell Syst 7:384-397.e6
Hogan, Louise E; Vasquez, Joshua; Hobbs, Kristen S et al. (2018) Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30. PLoS Pathog 14:e1006856
Shiboski, Caroline H; Baer, Alan N; Shiboski, Stephen C et al. (2018) Natural History and Predictors of Progression to Sjögren's Syndrome Among Participants of the Sjögren's International Collaborative Clinical Alliance Registry. Arthritis Care Res (Hoboken) 70:284-294
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429

Showing the most recent 10 out of 1541 publications